News
- BlueWillow Biologics’ Intranasal Bird Flu Vaccine Shows Signs of Broad Immune Response in Phase I Clinical Trial Published in Nature Communications
- H5 Influenza (Pandemic Flu) Clinical Trial Successful, Peer-Reivewed and Accepted for Publication
- BlueWillow Biologics to Present Significant Progress on Its Novel Intranasal Vaccine Technology at World Vaccine Congress Europe
Contact
BlueWillow Biologics, Inc.
2311 Green Rd. Suite A
Ann Arbor, MI 48105
734-302-4000
734-302-9150 fax
NanoBio Closes $11 Million Series C Financing
Funds Will Support Ongoing Clinical and Preclinical Development Programs ANN ARBOR, Mich. (November 28, 2012) – NanoBio Corporation announced today the closing of an $11 million Series C financing, including full participation from its existing investor syndicate. Proceeds from the financing will be used to advance the company’s development programs for herpes labialis (cold sores), […]
NanoBio Announces Data Presentation on Its Nanoemulsion Adjuvanted RSV Vaccine at IDWeek 2012
ANN ARBOR, Mich. and SAN DIEGO (October 15, 2012) – NanoBio Corporation announced today that results from its nanoemulsion adjuvanted RSV vaccine will be presented at IDWeek 2012™ taking place from Oct. 17-21 in San Diego.
NanoBio Promotes David Peralta to Chief Executive Officer
ANN ARBOR, Mich. (October 9, 2012) – NanoBio® Corporation today announced the promotion of David Peralta to chief executive officer. Mr. Peralta, who previously served as the company’s chief operating and financial officer, replaces James R. Baker, Jr. M.D., who recently joined Merck & Co. as the senior vice president, head global vaccine franchise. As […]
NanoBio to Report Data on Its Nanoemulsion Adjuvanted Intranasal RSV Vaccine at the 8th Annual International Respiratory Syncytial Virus Symposium
ANN ARBOR, Mich. and SANTA FE, N.M. (September 24, 2012) – NanoBio® Corporation announced today it will present data from three preclinical studies at the 8th Annual International Respiratory Syncytial Virus (RSV) Symposium taking place from Sept. 27-30 in Santa Fe, N.M.
NanoBio to Present Preclinical Data on Its Nanoemulsion Adjuvanted Intranasal RSV Vaccine and Novel Inhaled Cystic Fibrosis Therapy at 52nd Annual ICAAC Meeting
ANN ARBOR, Mich. (September 10, 2012) – NanoBio Corporation announced today it will present data from two separate preclinical studies at the 52nd Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) meeting currently underway in San Francisco.